Endo Announces Effectiveness of Form S-1 Registration Statement for Existing Shares
Endo, Inc. (OTCQX: NDOI) announced that the SEC has declared effective its Form S-1 registration statement for the resale of existing shares held by current shareholders. This move aims to enhance shareholder liquidity and create an orderly trading market for its common stock. Importantly, no new shares are being issued or sold, and the number of outstanding shares remains unchanged.
The company is now subject to the Securities Exchange Act of 1934, requiring regular SEC filings. Endo is targeting to list on the NYSE later in 2024, subject to approvals and conditions. Currently, Endo's shares trade on the OTCQX® Best Market, with financial disclosures and trading statistics available on www.otcmarkets.com.
Endo, Inc. (OTCQX: NDOI) ha annunciato che la SEC ha dichiarato efficace il proprio modulo di registrazione S-1 per la rivendita delle azioni esistenti detenute dagli azionisti attuali. Questa mossa mira a migliorare la liquidità degli azionisti e a creare un mercato di scambio ordinato per le sue azioni ordinarie. È importante sottolineare che non stanno venendo emesse o vendute nuove azioni e il numero di azioni in circolazione rimane invariato.
L'azienda è ora soggetta al Securities Exchange Act del 1934, che richiede registrazioni regolari presso la SEC. Endo ha l'obiettivo di quotarsi sul NYSE entro la fine del 2024, soggetto ad approvazioni e condizioni. Attualmente, le azioni di Endo sono negoziate sul mercato OTCQX® Best Market, con informazioni finanziarie e statistiche di trading disponibili su www.otcmarkets.com.
Endo, Inc. (OTCQX: NDOI) anunció que la SEC ha declarado efectivo su formulario de registro S-1 para la reventa de acciones existentes en poder de los accionistas actuales. Este movimiento tiene como objetivo mejorar la liquidez de los accionistas y crear un mercado de negociación ordenado para sus acciones ordinarias. Es importante señalar que no se están emitiendo ni vendiendo nuevas acciones, y el número de acciones en circulación permanece sin cambios.
La empresa ahora está sujeta a la Ley de Intercambio de Valores de 1934, que requiere presentaciones regulares ante la SEC. Endo está planeando cotizar en la NYSE a finales de 2024, sujeto a aprobaciones y condiciones. Actualmente, las acciones de Endo se negocian en el mercado OTCQX® Best Market, con divulgaciones financieras y estadísticas de negociación disponibles en www.otcmarkets.com.
Endo, Inc. (OTCQX: NDOI)는 SEC가 기존 주주가 보유한 주식 재판매를 위한 S-1 등록 양식을 효력 있게 발표했다고 밝혔습니다. 이 조치는 주주 유동성을 향상시키고 회사의 보통주에 대한 질서 있는 거래 시장을 조성하기 위한 것입니다. 특히, 신규 주식이 발행되거나 판매되지 않으며 발행주식 수는 변하지 않습니다.
회사는 이제 1934년 증권거래법의 적용을 받으며, 정기적인 SEC 제출이 요구됩니다. Endo는 2024년 말 NYSE에 상장할 계획이며, 이는 승인과 조건에 따라 달라질 수 있습니다. 현재 Endo의 주서는 OTCQX® Best Market에서 거래되고 있으며, 재무 공시 및 거래 통계는 www.otcmarkets.com에서 확인할 수 있습니다.
Endo, Inc. (OTCQX: NDOI) a annoncé que la SEC a déclaré effectif son formulaire d'enregistrement S-1 pour la revente d'actions existantes détenues par les actionnaires actuels. Ce mouvement vise à améliorer la liquidité des actionnaires et à créer un marché de négociation ordonné pour ses actions ordinaires. Il est important de noter que aucune nouvelle action n'est émise ou vendue et que le nombre d'actions en circulation reste inchangé.
L'entreprise est désormais soumise à la loi sur les échanges de valeurs mobilières de 1934, ce qui nécessite des dépôts réguliers auprès de la SEC. Endo vise à être coté à la NYSE d'ici la fin de 2024, sous réserve d'approbations et de conditions. Actuellement, les actions d'Endo se négocient sur le marché OTCQX® Best Market, avec des divulgations financières et des statistiques de trading disponibles sur www.otcmarkets.com.
Endo, Inc. (OTCQX: NDOI) hat bekannt gegeben, dass die SEC ihre S-1-Registrierungsformulare für den Wiederverkauf von bestehenden Aktien, die von aktuellen Aktionären gehalten werden, für wirksam erklärt hat. Dieser Schritt zielt darauf ab, die Liquidität der Aktionäre zu erhöhen und einen geordneten Handelsmarkt für die Stammaktien zu schaffen. Wichtig ist, dass keine neuen Aktien emittiert oder verkauft werden und die Anzahl der ausgegebenen Aktien unverändert bleibt.
Das Unternehmen unterliegt nun dem Securities Exchange Act von 1934, der regelmäßige SEC-Einreichungen verlangt. Endo plant die Notierung an der NYSE Ende 2024, vorbehaltlich von Genehmigungen und Bedingungen. Derzeit werden Endos Aktien auf dem OTCQX® Best Market gehandelt, mit finanziellen Offenlegungen und Handelsstatistiken, die auf www.otcmarkets.com verfügbar sind.
- Registration statement effectiveness may improve stock liquidity
- Potential NYSE listing in 2024 could increase visibility and trading volume
- No dilution to existing shareholders as no new shares are being issued
- None.
As previously announced, Endo is neither issuing nor selling new shares of its common stock in connection with the Registration Statement, and there will be no change to the number of outstanding shares. The Company is now subject to the Securities Exchange Act of 1934, requiring it to, among other things, file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC on an ongoing basis.
Endo, which is focused on creating long-term value for stakeholders through a diversified portfolio of on-market medicines and a pipeline of innovative and differentiated product candidates, is targeting to have the Company's shares of common stock begin trading on the New York Stock Exchange (NYSE) later in 2024, subject to required approvals and other customary conditions.
Shares of Endo's common stock currently trade on the OTCQX® Best Market. U.S. investors can find current financial disclosure and trading statistics, including Real-Time Level 2 quotes, for Endo on www.otcmarkets.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations of offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, any statements related to the listing, uplisting or trading of the Company's equity on NYSE, including the timing and outcome of the NYSE's review, the Company's products, therapies and pipeline, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-announces-effectiveness-of-form-s-1-registration-statement-for-existing-shares-302211546.html
SOURCE Endo, Inc.
FAQ
What is the purpose of Endo's Form S-1 registration statement?
Is Endo (NDOI) issuing new shares with this registration statement?
When does Endo (NDOI) plan to list on the New York Stock Exchange?
Where are Endo's (NDOI) shares currently traded?
